EFM
IMNM icon

E Fund Management’s Immunome IMNM Stock Holding History

E Fund Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Sell
11,727
-7,911
-40% -$169K 0.01% 420
2026
Q1 		$429K Buy
+19,638
New +$437K 0.01% 315

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

E Fund Management's IMNM Position: Q2 2026 in Review

E Fund Management reduced its Immunome (IMNM) stake by 40% in Q2 2026, selling an estimated $169K and leaving 11,727 shares worth $248K. The position accounts for 0.01% of the portfolio, ranked #420.

E Fund Management first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $429K in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • E Fund Management held 11,727 shares of Immunome worth $248K as of Q2 2026.
  • E Fund Management sold 7,911 Immunome shares in Q2 2026, an estimated $169K.
  • Immunome made up 0.01% of E Fund Management's portfolio in Q2 2026, its #420 holding.
  • E Fund Management first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Immunome position peaked at $429K in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.